A Multicenter Real‐World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma Treated With a Polatuzumab Vedotin‐Based Regimen in a Compassionate Use Program in Malaysia
Pola-BR has a favorable safety profile for R/R DLBCL treatment in Malaysia, although larger sample sizes and longer follow-ups are needed to confirm these results.
Authors
- Tan Yong Seng
- Siew‐Cheok Ng
- K. Kamini
- Izzah Athirah Rosli (ORCID: https://orcid.org/0000-0002-6501-8565)
- Veena Selvaratnam
- Ahlam Naila Kori (ORCID: https://orcid.org/0000-0003-1337-5664)
- Lee Ping Chew (ORCID: https://orcid.org/0000-0002-8243-5475)
- Nor Asiah Muhamad (ORCID: https://orcid.org/0000-0002-7772-2103)
- S A W Fadilah (ORCID: https://orcid.org/0000-0003-2092-7703)
- Chiang Su Kien
- Soo Min Lim
- Nor Azimah Ismail (ORCID: https://orcid.org/0000-0003-2441-0699)
Institutions
- Ministry of Health (MY)
- Hospital Tengku Ampuan Afzan (MY)
- Hospital Pulau Pinang (MY)
- Sarawak General Hospital (MY)
- Sultanah Aminah Hospital (MY)
- University Kebangsaan Malaysia Medical Centre (MY)
- Institut Penyelidikan Veterinar (MY)
- Subang Jaya Medical Centre (MY)
- KPJ Ampang Puteri Specialist Hospital (MY)
Publication Details
- Journal
- Asia-Pacific Journal of Clinical Oncology
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1111/ajco.14208
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47